Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2569653rdf:typepubmed:Citationlld:pubmed
pubmed-article:2569653lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:2569653lifeskim:mentionsumls-concept:C0005823lld:lifeskim
pubmed-article:2569653lifeskim:mentionsumls-concept:C0301630lld:lifeskim
pubmed-article:2569653lifeskim:mentionsumls-concept:C0732165lld:lifeskim
pubmed-article:2569653lifeskim:mentionsumls-concept:C0128635lld:lifeskim
pubmed-article:2569653pubmed:issue3lld:pubmed
pubmed-article:2569653pubmed:dateCreated1989-9-8lld:pubmed
pubmed-article:2569653pubmed:abstractTextA hypotensive effect of an orally-administered cyclopeptide somatostatin analog, MK-678, has been demonstrated in a hypertensive diabetic rat model. Sustained blood pressure reduction failed to occur when the drug was administered to the spontaneously hypertensive rat. The mechanism of hypotension appears independent of effects on a variety of hormones including insulin, glucagon, growth hormone, and components of the renin-angiotensin system including renin activity, plasma angiotensin converting enzyme, and aldosterone.lld:pubmed
pubmed-article:2569653pubmed:languageenglld:pubmed
pubmed-article:2569653pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2569653pubmed:citationSubsetIMlld:pubmed
pubmed-article:2569653pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2569653pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2569653pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2569653pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2569653pubmed:statusMEDLINElld:pubmed
pubmed-article:2569653pubmed:issn0024-3205lld:pubmed
pubmed-article:2569653pubmed:authorpubmed-author:HartmannJJlld:pubmed
pubmed-article:2569653pubmed:authorpubmed-author:ChenS LSLlld:pubmed
pubmed-article:2569653pubmed:authorpubmed-author:SlaterEElld:pubmed
pubmed-article:2569653pubmed:authorpubmed-author:SzemplinskiMMlld:pubmed
pubmed-article:2569653pubmed:issnTypePrintlld:pubmed
pubmed-article:2569653pubmed:volume45lld:pubmed
pubmed-article:2569653pubmed:ownerNLMlld:pubmed
pubmed-article:2569653pubmed:authorsCompleteYlld:pubmed
pubmed-article:2569653pubmed:pagination267-74lld:pubmed
pubmed-article:2569653pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:2569653pubmed:meshHeadingpubmed-meshheading:2569653-...lld:pubmed
pubmed-article:2569653pubmed:meshHeadingpubmed-meshheading:2569653-...lld:pubmed
pubmed-article:2569653pubmed:meshHeadingpubmed-meshheading:2569653-...lld:pubmed
pubmed-article:2569653pubmed:meshHeadingpubmed-meshheading:2569653-...lld:pubmed
pubmed-article:2569653pubmed:meshHeadingpubmed-meshheading:2569653-...lld:pubmed
pubmed-article:2569653pubmed:meshHeadingpubmed-meshheading:2569653-...lld:pubmed
pubmed-article:2569653pubmed:meshHeadingpubmed-meshheading:2569653-...lld:pubmed
pubmed-article:2569653pubmed:meshHeadingpubmed-meshheading:2569653-...lld:pubmed
pubmed-article:2569653pubmed:meshHeadingpubmed-meshheading:2569653-...lld:pubmed
pubmed-article:2569653pubmed:meshHeadingpubmed-meshheading:2569653-...lld:pubmed
pubmed-article:2569653pubmed:meshHeadingpubmed-meshheading:2569653-...lld:pubmed
pubmed-article:2569653pubmed:meshHeadingpubmed-meshheading:2569653-...lld:pubmed
pubmed-article:2569653pubmed:meshHeadingpubmed-meshheading:2569653-...lld:pubmed
pubmed-article:2569653pubmed:meshHeadingpubmed-meshheading:2569653-...lld:pubmed
pubmed-article:2569653pubmed:year1989lld:pubmed
pubmed-article:2569653pubmed:articleTitleBlood pressure reduction in hypertensive-diabetic rats by the somatostatin analog MK-678.lld:pubmed
pubmed-article:2569653pubmed:affiliationMerck Sharp & Dohme Research Laboratories, Department of Biochemical Endocrinology, Rahway, NJ 07065.lld:pubmed
pubmed-article:2569653pubmed:publicationTypeJournal Articlelld:pubmed